ARGENX SE
ARGX · XNASCIK 1697862fmd_15S216ZZ7GMX0CBJDGH2BPSANDManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 20 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 21 | 78 | 41 | 497 | 10 | 36 | – | – |
| Cost of revenue | – | – | – | – | 29 | 118 | 227 | 451 |
| Gross profit | – | – | – | – | (19) | (82) | – | – |
| Research and development | 84 | 221 | 371 | 581 | 663 | 859 | 983 | 1,364 |
| Selling, general and administrative | – | – | – | 368 | 472 | 712 | 1,055 | 1,367 |
| Operating income | (82) | (199) | (478) | (349) | (720) | (425) | (22) | 1,054 |
| Interest expense | – | – | 8 | 5 | 4 | 1 | 2 | 4 |
| Income before taxes | – | (176) | (605) | (400) | (729) | (304) | 85 | 1,279 |
| Income tax expense | – | 5 | 3 | 9 | (20) | (9) | (748) | (13) |
| Net income from continuing operations | – | (181) | (608) | (408) | (710) | (295) | 833 | 1,292 |
| Net income | (67) | (181) | (608) | (408) | (710) | (295) | 833 | 1,292 |
| Net income to common shareholders | – | – | (608) | (408) | (710) | (295) | 833 | 1,292 |